NorthSpring Capital Partners
VC Fund
Cambridge, Canada
NorthSpring Capital Partners is a VC fund in Cambridge focused on Health Care and Medical Device. NorthSpring Capital Partners provides risk capital to small and medium sized companies with the goal of creating value. Investments range between $250,000 and $1 million in the form of subordinated debt and/or equity across a variety of traditional industries located in Southern Ontario. NorthSpring takes a flexible approach when reviewinginvestment opportunities and tailors its investment structure to fit the unique aspects of the business.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 26%
Last updated:
For AI agents: llms.txt
Industries NorthSpring Capital Partners invests in
Stages NorthSpring Capital Partners invests in
Countries NorthSpring Capital Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $675k–$5M
- Pre-Seed
- $1.6M–$1.8M
- Series A
- $5M–$11M
Investment Focus
Industry
- Health Care 9 (47%)
- Medical Device 8 (42%)
- Software 5 (26%)
- Medical 4 (21%)
- Biotechnology 4 (21%)
Stage
- Seed 10 (53%)
- Series A 3 (16%)
- Pre-Seed 2 (11%)
- Angel 1 (5%)
- Debt Financing 1 (5%)
Country
- Canada 17 (89%)
- United States 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Brian Hunter
President
|
President | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mesosil
|
Mesosil develops responsive antimicrobial materials to prevent infection at the medical device-tissue interface, with lifetime length of effect. Our technology is ideally suited for dental restoratives and dental implant surfaces. The result is greatly improved patient outcome with no change to practitioner workflow, reducing the likelihood ofrecurrent caries and detachment of dental restorations, or peri-implant wound infection that could result in implant loss and implant revision. | $1.6M / Seed / Jun 05, 2024 | |
Noa Therapeutics
|
Noa Therapeutics is a preclinical biotech firm that is leading the way in the development of multimodal treatments. To simplify the course of care for patients in need, we developed a single, non-steroidal, small molecule with tunable efficacy | $1.6M / Pre-Seed / Mar 06, 2024 | |
YOURIKA
|
YOURIKA combines years of AI research from the University of Waterloo (Top 5 in AI) with our proprietary technology and domain expertise to make smarter and more connected learning products. This includes our own platform, ORBITS, that liberates teenage students to work smarter when learning remotely. | $2.6M / Seed / Oct 31, 2022 | |
Oncoustics AI
|
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers. | $5M / Seed / Jul 21, 2022 | |
Able Innovations
|
Able Innovations is developing advanced medical devices to tackle the pressing problem of patient transfer in healthcare. Their technology is revolutionizing the quality of care provision - providing a safe, efficient, and dignified care experience for patients and caregivers. | $3.5M / Seed / Jun 13, 2022 | |
Rehabtronics
|
Rehabtronics is a technology development firm that focuses on solutions for physical rehab. | $1.6M / Venture - Series Unknown / Nov 18, 2021 | |
|
Mesosil
|
Mesosil develops responsive antimicrobial materials to prevent infection at the medical device-tissue interface, with lifetime length of effect. Our technology is ideally suited for dental restoratives and dental implant surfaces. The result is greatly improved patient outcome with no change to practitioner workflow, reducing the likelihood ofrecurrent caries and detachment of dental restorations, or peri-implant wound infection that could result in implant loss and implant revision. | $675K / Seed / Jul 13, 2021 | |
Workwolf
|
Workwolf is a recruitment services company that combines human recruiters with proprietary AI and psychometric technology to deliver predictive hiring intelligence at disruptive pricing. The company addresses a fundamental inefficiency in the $150B+ recruitment industry: traditional agencies charge 15-25% of candidate salary for subjectiveassessments with no performance accountability. Workwolf’s technology-enabled model delivers measurable quality improvements at significantly lower cost per hire. The proprietary technology platform includes two core components: Smart Resume Screening for contextual qualification matching, and Packfinder™ psychometrics for role-specific performance prediction. Unlike generic assessment tools, Packfinder™ models are calibrated using client performance data, creating organization-specific predictions that improve with scale. The business model starts at fees as low as 4% of annual salary for high-volume roles, rather than percentage-based fees of 15-25%, creating favorable unit economics for high-volume clients while maintaining strong margins through technology leverage. This pricing structure aligns incentives around retention rather than salary inflation. Target customers are mid-market companies with consistent hiring volume (2+ hires/month) across multiple locations—particularly retail, hospitality, healthcare, logistics, and call centers. These segments offer predictable demand and benefit most from Workwolf’s pattern recognition capabilities across distributed operations. The platform generates compounding data advantages: each hire provides performance outcome data that refines predictive models, creating a defensible moat as the system processes more hiring decisions within and across client organizations. Workwolf is headquartered in Toronto, Canada. | $1.8M / Pre-Seed / Dec 15, 2020 | |
Forcen
|
Forcen is a tier 1 supplier of Force/Torque sensor systems and edge intelligence to robotics OEMs. A comprehensive plug-and-play sensing network for your robot's force/torque systems. | Seed / Sep 16, 2020 | |
FluidAI Medical
|
FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery. | $2.7M / Seed / Apr 14, 2020 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does NorthSpring Capital Partners invest in?
NorthSpring Capital Partners invests primarily in Health Care, Medical Device and Software startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is NorthSpring Capital Partners's check size?
NorthSpring Capital Partners typically joins rounds of $675k–$5M at Seed, $1.6M–$1.8M at Pre-Seed and $5M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds NorthSpring Capital Partners participates in.
How do I contact NorthSpring Capital Partners?
Public channels for NorthSpring Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NorthSpring Capital Partners?
The team at NorthSpring Capital Partners includes Brian Hunter (President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
